Summary
A beta amyloid (Aβ) peptide vaccine can decrease brain Aβ deposition as well as partially protect against memory loss in a transgenic mouse model for Alzheimer’s Disease (AD) that expresses human amyloid precursor protein (APP) and presenilin-1 (PS-1). Current information indicates that antibodies elicited by this vaccine probably mediate the protective effect, although the precise mechanism of action for these antibodies has not yet been established. One of our major interests has been the more extensive characterization of the Aβ vaccine, as well as developing methods for optimizing and maximizing this vaccine strategy. Optimization is important since we have observed that at least three vaccinations with the Aβ peptide vaccine were needed to elicit a significant antibody response. Also, a less robust antibody response to the Aβ vaccine was noted in older animals (i.e., 23 months of age) than in younger animals (4 and 15 months of age).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bacskai J, Kajdasz ST, Christie RH, Carter C, Games D, Seubert P, Schenk D, Hyman BT (2001) Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nature Med 7:369–372.
Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson- Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nature Med 6:916–919.
DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM (2001) Peripheral anti- A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci USA 98:8850–8855.
Dickey CA, Morgan DG, Kudchodkar S, Weiner DB, Bai Y, Cao C, Gordon MN, Ugen KE (2001) Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer’s disease-associated beta-amyloid 1–42 peptide. DNA Cell Biol 20:723–729.
Duff K, Eckman C, Zehr C, Yu X, Prada CM, Perez-tur J, Hutton M, Buee L, Harigaya Y, Yager D, Morgan D, Gordon M, Holcomb L, Refolo L, Zenk B, Hardy J, Younkin S (1996) Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 383:710–713.
Frenkel D, Katz O, Solomon B (2000a) Immunization against Alzheimer’s beta -amyloid plaques via EFRH phage administration. Proc Natl Acad Sci USA 97:11455–11459.
Frenkel D, Solomon B, Benhar I (2000b) Modulation of Alzheimer’s beta-amyloid neurotoxicity by site-directed single-chain antibody. J Neuroimmunol 106:23–31.
Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, Guido T, Hagopian S, Johnson-Wood K, Khan K, Lee M, Leibowitz P, Lieberburg I, Little S, Masliah E, McConlogue L, Montoya-Zavala M, Mucke L, Paganini L, Penniman E, Power M, Schenk D, Seubert P, Snyder B, Soriano F, Tan H, Vitale J, Wadsworth S, Wolozin B, Zhao J (1995) Alzheimer-type neuropathology in transgenic mice overexpress- ing V717F beta-amyloid precursor protein. Nature 373:523–527.
Hardy J (1997) Amyloid, the presenilins and Alzheimer’s disease. Trends Neurosci 20:154–159.
Hardy J, Allsop D (1991). Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol Sci 12:383–388.
Hsiao K (1998) Strain dependent and invariant features of transgenic mice expressing Alzhei-mer amyloid precursor proteins. Prog Brain Res 117:335–341.
Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G (1996) Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274:99–102.
Huang T H, Yang DS, Plaskos NP, Go S, Yip CM, Fraser PE, Chakrabartty A (2000) Structural studies of soluble oligomers of the Alzheimer beta-amyloid peptide. J Mol Biol 297:73–87.
Janus C, Pearson J, McLaurin, J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Home P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, Bergeron C, Fraser PE, St George-Hyslop P, Westaway D (2000) A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer’s disease. Nature 408:979–982.
Miller RA (1995) Immune systems. In: Masoro E (ed) Handbook of physiology. Section 11: Physiology of aging. New York: Oxford University Press, pp 555–590.
Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, HardyJ, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW (2000) A beta peptide vaccination prevents memory loss in an animal model of Alzheimer’s disease. Nature 408:982–985.
Podlisny MB, Walsh DM, Amarante P, Ostaszewski BL, Stimson ER, Maggio JE, Teplow DB, Selkoe DJ (1998) Oligomerization of endogenous and synthetic amyloid beta-protein at nanomolar levels in cell culture and stabilization of monomer by Congo red. Biochemistry 37:3602–3611.
Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400:173–177.
Solomon B, Koppel R, Hanan E, Katzav T (1996) Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Proc Natl Acad Sci USA 93:452–455.
Solomon B, Koppel R, Frankel D, Hanan-Aharon E (1997) Disaggregation of Alzheimer beta- amyloid by site-directed mAb. Proc Natl Acad Sci USA 94:4109–4112.
Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, Burki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M, Sommer B (1997) Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA 94:13287–13292.
Suh YH (1997). An etiological role of amyloidogenic carboxyl-terminal fragments of the beta- amyloid precursor protein in Alzheimer’s disease. J Neurochem 68:1781–1791.
Weiner HL, Lemere CA, Maron, R, Spooner ET, Grenfell, TJ, Mori C, Issazadeh S, Hancock WW, Selkoe DJ (2000) Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer’s disease. Ann Neurol 48:567–579.
Wilcock DM, Gordon MN, Ugen KE, Gottschall PE, DiCarlo G, Dickey C, Boyett KW, Jantzen PT, Connor KE, Melachrino J, Hardy J, Morgan D (2001) Number of Abeta inoculations in APP+PS1 transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels. DNA Cell Biol 20:731–736.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Cao, C. et al. (2003). Characterization of Amyloid Beta Vaccination Strategies in Mice. In: Selkoe, D.J., Christen, Y. (eds) Immunization Against Alzheimer’s Disease and Other Neurodegenerative Disorders. Research and Perspectives in Alzheimer’s Disease. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59332-1_3
Download citation
DOI: https://doi.org/10.1007/978-3-642-59332-1_3
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-63937-1
Online ISBN: 978-3-642-59332-1
eBook Packages: Springer Book Archive